CF end point commentary.
Division of Pulmonary, Allergy, and Rheumatology Products, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA. Electronic address: Anthony.Durmowicz@fda.hhs.gov.
Anthony G
AG
Durmowicz
D003550:Cystic Fibrosis; D006801:Humans